![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
A California-based biotech company is already stealing the show during Wednesday’s premarket after the company announced a CEO transition and an estimated 83% reduction in To read the full...
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and...
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo...
– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio...
– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place...
SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0145 | -1.47959183673 | 0.98 | 1.03 | 0.95 | 224118 | 0.98255932 | CS |
4 | 0.0155 | 1.63157894737 | 0.95 | 1.07 | 0.9165 | 206922 | 0.99983898 | CS |
12 | 0.1105 | 12.9239766082 | 0.855 | 1.09 | 0.84 | 316720 | 0.95861904 | CS |
26 | -0.0345 | -3.45 | 1 | 1.0999 | 0.8 | 194519 | 0.95595631 | CS |
52 | -0.1045 | -9.76635514019 | 1.07 | 1.6 | 0.69 | 295891 | 1.03451729 | CS |
156 | -6.4445 | -86.9703103914 | 7.41 | 8.42 | 0.69 | 294595 | 2.300998 | CS |
260 | -27.3245 | -96.5871332626 | 28.29 | 39.605 | 0.69 | 280370 | 8.02671164 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions